Sputum and serum calprotectin are useful biomarkers during CF exacerbation

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P. Greening

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

BACKGROUND: Adequate monitoring of cystic fibrosis lung disease is difficult. CF exacerbation offers a unique setting to test the utility of biomarkers in the assessment of changing airways inflammation. We hypothesised that levels of calprotectin in sputum (and serum) would change informatively following treatment of an exacerbation. METHODS: 27 patients with CF were recruited at onset of pulmonary exacerbation. Sputum and serum were collected at the start and end of anti-biotic therapy. Sputum calprotectin, interleukin-8 (IL8), and myeloperoxidase (MPO) were measured, as were serum calprotectin, CRP and vascular endothelial growth factor (VEGF). RESULTS: Sputum calprotectin decreased following treatment of an exacerbation (p
Original languageEnglish
Pages (from-to)193-198
Number of pages6
JournalJournal of Cystic Fibrosis
Issue number3
Publication statusPublished - 2010

Keywords / Materials (for Non-textual outputs)

  • Adolescent Adult Biological Markers/analysis/blood Cystic Fibrosis/*blood Disease Progression Female Humans Leukocyte L1 Antigen Complex/analysis/*blood Male Middle Aged Sputum/*chemistry Young Adult


Dive into the research topics of 'Sputum and serum calprotectin are useful biomarkers during CF exacerbation'. Together they form a unique fingerprint.

Cite this